Contents

19 February 2014
Vol 6, Issue 224
  • Contents

    • Editorial

      • UK Biobank Data: Come and Get It

        UK Biobank invites scientists to make use of the vast (and growing) amounts of data in this open-access resource for public health research.

    • Commentary

    • Research Articles

      • Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

        Circulating tumor DNA can be used in a variety of clinical and investigational settings across tumor types and stages for screening, diagnosis, and identifying mutations responsible for therapeutic response and drug resistance.

      • Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

        CD19 CAR T cell therapy induces complete remissions in 88% of 16 adult patients with relapsed or refractory acute lymphoblastic leukemia.

      • Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

        Colorectal cancers that become resistant to EGFR inhibitors through a variety of mechanisms can be effectively treated by inhibiting MEK in conjunction with EGFR.

    • Editors' Choice

      • Seeking Harmony Among Cancer Killers

        A rationally devised duet of apoptotic drugs and immune adjuvants boosts antitumor activity.

      • Boosting Metabolism by Sweetening the Gut

        Dietary fiber provides metabolic benefits, including body weight and glucose control, through microbiota-induced intestinal glucose production.

About The Cover

Cover image expansion

ONLINE COVER The Tell-Tale Needle in the Haystack. This illustration shows a tumor shedding molecules of DNA into the bloodstream, where they can be detected and analyzed. Although the circulating tumor DNA (ctDNA) is easily identifiable in this image, the real-life scenario presents a challenge, with very rare molecules of ctDNA concealed in a large volume of normal blood. However, those molecules are there, and Bettegowda et al. now demonstrate that even early stage tumors in many different organs shed ctDNA that can be identified in a sample of the patient’s blood. In a related paper, Misale and coauthors show how information derived from ctDNA can be used to detect treatment-resistant colon cancer and demonstrate a method for overcoming this resistance. [CREDIT: C. BICKEL/SCIENCE TRANSLATIONAL MEDICINE]